INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,395,804 | -17.1% | 26,796 | +0.8% | 0.00% | -25.0% |
| Q2 2023 | $1,684,059 | +9.1% | 26,596 | -6.7% | 0.00% | 0.0% |
| Q1 2023 | $1,543,058 | +2.3% | 28,496 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,508,008 | +13.8% | 28,496 | +0.1% | 0.00% | +33.3% |
| Q3 2022 | $1,325,000 | -18.5% | 28,466 | 0.0% | 0.00% | -25.0% |
| Q2 2022 | $1,625,000 | -3.6% | 28,466 | +3.3% | 0.00% | +33.3% |
| Q1 2022 | $1,686,000 | +16.9% | 27,546 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,442,000 | +41.9% | 27,546 | +1.1% | 0.00% | +50.0% |
| Q3 2021 | $1,016,000 | -8.6% | 27,253 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,112,000 | +27.2% | 27,253 | +5.8% | 0.00% | 0.0% |
| Q1 2021 | $874,000 | +6.6% | 25,768 | -0.0% | 0.00% | 0.0% |
| Q4 2020 | $820,000 | +22.9% | 25,778 | -0.8% | 0.00% | 0.0% |
| Q3 2020 | $667,000 | +21.1% | 25,988 | +21.2% | 0.00% | +100.0% |
| Q2 2020 | $551,000 | +67.0% | 21,448 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $330,000 | -55.2% | 21,448 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $736,000 | +360.0% | 21,448 | 0.0% | 0.00% | – |
| Q3 2019 | $160,000 | -42.4% | 21,448 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $278,000 | +10.8% | 21,448 | +4.1% | 0.00% | 0.0% |
| Q1 2019 | $251,000 | +6.8% | 20,608 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $235,000 | -47.1% | 20,608 | +0.7% | 0.00% | 0.0% |
| Q3 2018 | $444,000 | +22.7% | 20,462 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $362,000 | +0.8% | 20,462 | +19.9% | 0.00% | 0.0% |
| Q1 2018 | $359,000 | +52.1% | 17,062 | +4.9% | 0.00% | 0.0% |
| Q4 2017 | $236,000 | -3.7% | 16,265 | +5.0% | 0.00% | 0.0% |
| Q3 2017 | $245,000 | +27.6% | 15,495 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $192,000 | -23.8% | 15,495 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $252,000 | +7.7% | 15,495 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $234,000 | -0.8% | 15,495 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $236,000 | -58.7% | 15,495 | +5.1% | 0.00% | -50.0% |
| Q2 2016 | $572,000 | +50.5% | 14,745 | +7.8% | 0.00% | +100.0% |
| Q1 2016 | $380,000 | -37.8% | 13,677 | +20.4% | 0.00% | -50.0% |
| Q4 2015 | $611,000 | – | 11,357 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |